A Phase II Trial of Preoperative Cisplatin and Bevacizumab in Estrogen Receptor (ER) Negative, Progesterone (PR) Negative, Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 25 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2020.
- 10 Jun 2017 Biomarkers information updated
- 22 Mar 2017 Planned End Date changed from 1 Dec 2013 to 1 Jun 2017.